sTIM-3及其配体Gal-9、HMGB1与2型糖尿病并发冠心病的相关性研究

doi:10.11958/20221307

天津医药 ›› 2023, Vol. 51 ›› Issue (3): 294-298.doi: 10.11958/20221307

sTIM-3及其配体Gal-9、HMGB1与2型糖尿病并发冠心病的相关性研究

刘艳秋¹(), 范海迪¹, 侯海燕², 孙健¹, 林宁^△()

1 淮安市第一人民医院分院检验科（邮编223002）
2 南京市秦淮区疾病预防控制中心检验科
3 南京医科大学附属淮安第一医院检验科

收稿日期:2022-08-22 修回日期:2022-10-12 出版日期:2023-03-15 发布日期:2023-03-02
通讯作者: 林宁 E-mail:hayylyq@126.com;hayyln@126.com
作者简介:刘艳秋（1979），女，副主任技师，主要从事糖尿病的发病机制方面研究。E-mail：hayylyq@126.com
基金资助:
江苏省淮安市自然科学研究计划基金资助项目(HAB202137)

Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease

LIU Yanqiu¹(), FAN Haidi¹, HOU Haiyan², SUN Jian¹, LIN Ning^△()

1 Department of Clinical Laboratory, Branch Hospital of Huai'an First People's Hospital, Huai'an 223002, China
2 Department of Clinical Laboratory, Qinhuai District Center for Disease Control and Prevention
3 Department of Clinical Laboratory, Huai'an First Hospital Affiliated to Nanjing Medical University

Received:2022-08-22 Revised:2022-10-12 Published:2023-03-15 Online:2023-03-02
Contact: LIN Ning E-mail:hayylyq@126.com;hayyln@126.com

刘艳秋, 范海迪, 侯海燕, 孙健, 林宁. sTIM-3及其配体Gal-9、HMGB1与2型糖尿病并发冠心病的相关性研究[J]. 天津医药, 2023, 51(3): 294-298.

LIU Yanqiu, FAN Haidi, HOU Haiyan, SUN Jian, LIN Ning. Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease[J]. Tianjin Medical Journal, 2023, 51(3): 294-298.

摘要/Abstract

摘要： Objective To investigate the relationship between serum soluble T cell immunoglobulin and mucin domain-3 (sTIM-3), galectin-9 (Gal-9) and high mobility group protein B1 (HMGB1) levels in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD). Methods Fifty patients with T2DM were used as the T2DM group, and fifty-two patients with T2DM complicated with CHD were selected as the T2DM+CHD group. Forty-eight healthy physical examination subjects were selected as the control group (Con group). Serum levels of sTIM-3, Gal-9 and HMGB1 were detected by enzyme-linked immunosorbent assay (ELISA). Spearman correlation analysis was used to analyze the correlation between serum sTIM-3, Gal-9, HMGB1, fasting blood glucose (FBG) and high-sensitivity C-reactive protein (hs-CRP). Receiver operating characteristic curve (ROC) was used to analyse the diagnostic capability of sTIM-3, Gal-9 and their combination in T2DM complicated with CHD. Logistic regression was used to investigate the risk factors of T2DM complicated with CHD. Results Compared with the Con group, sTIM-3, Gal-9 and HMGB1 were significantly increased in the T2DM group and the T2DM+CHD group (P<0.05). Compared with the T2DM group, sTIM-3 and Gal-9 were significantly increased in the T2DM+CHD group (P<0.05), and there was no significant difference in HMGB1. FBG and hs-CRP were positively correlated with sTIM-3, Gal-9 and HMGB1, sTIM-3 was positively correlated with Gal-9 and HMGB1, and Gal-9 was positively correlated with HMGB1 (P<0.05). ROC curve analysis showed that the area under the curve of serum sTIM-3 and Gal-9 in the diagnosis of T2DM complicated with CHD was 0.812 (95%CI: 0.743-0.882). Logistic regression analysis showed that increased body mass index, sTIM-3 and Gal-9 were risk factors for T2DM complicated with CHD. Conclusion Increased serum levels of sTIM-3 and Gal-9 are risk factors for T2DM complicated with CHD.

关键词: 糖尿病，2型, 冠状动脉疾病, 半乳糖凝集素类, 高迁移率族蛋白质类, 可溶性T细胞免疫球蛋白及黏蛋白分子-3

Key words: diabetes mellitus, type 2, coronary disease, galectins, high mobility group proteins, sTIM-3

中图分类号:

R392.6

图/表 5

参考文献 23

[1]	GUO J, SMITH S M. Newer drug treatments for type 2 diabetes[J]. BMJ, 2021, 373:n1171. doi:10.1136/bmj.n1171.
[2]	THOMAS M C. Type 2 diabetes and heart failure:Challenges and solutions[J]. Curr Cardiol Rev, 2016, 12(3): 249-255. doi:10.2174/1573403x12666160606120254.
[3]	DIXON K O, DAS M, KUCHROO V K. Human disease mutations highlight the inhibitory function of TIM-3[J]. Nat Genet, 2018, 50(12):1640-1641. doi:10.1038/s41588-018-0289-3.
[4]	GROSSMAN T B, MINIS E, LOEB-ZEITLIN S E, et al. Soluble T cell immunoglobulin mucin domain 3(sTim-3)in maternal sera:A potential contributor to immune regulation during pregnancy[J]. J Matern Fetal Neonatal Med, 2021, 34(24):4119-4122. doi:10.1080/14767058.2019.1706471.
[5]	HASTINGS W D, ANDERSON D E, KASSAM N, et al. TIM-3 is expressed on activated human CD4⁺ T cells and regulates Th1 and Th17 cytokines[J]. Eur J Immunol, 2009, 39:2492-2501. doi:10.1002/eji.200939274.
[6]	CHEN S, DONG Z, YANG P, et al. Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis[J]. Cancer Lett, 2017, 394:22-32. doi:10.1016/j.canlet.2017.02.011.
[7]	钟玉梅, 陈洋, 罗小超, 等. Tim-3调控巨噬细胞极化在类风湿性关节炎中的研究进展[J]. 天津医药, 2020, 48(9):898-902.
	ZHONG Y M, CHEN Y, LUO X C, et al. Research progress of Tim-3 regulating the polarization of macrophage in rheumatoid arthritis[J]. Tianjin Med J, 2020, 48(9):898-902. doi:10.11958/20200625.
[8]	KAMATA Y, TAKANO K, KISHIHARA E, et al. Distinct clinical characteristics and therapeutic modalities for diabetic ketoacidosis in type 1 and type 2 diabetes mellitus[J]. J Diabetes Complications, 2017, 31(2):468-472. doi:10.1016/j.jdiacomp.2016.06.023.
[9]	NYAMBUYA T M, DLUDLA P V, MXINWA V, et al. T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus:A systematic review and meta-analysis[J]. Clin Immunol, 2020, 210:108313. doi:10.1016/j.clim.2019.108313.
[10]	WANG H, CAO K, LIU S, et al. Tim-3 expression causes NK cell dysfunction in type 2 diabetes patients[J]. Front Immunol, 2022, 13:852436. doi:10.3389/fimmu.2022.852436.
[11]	石新慧. 可溶性Tim-3在疾病中的表达及其意义的研究[D]. 北京: 中国人民解放军军事医学科学院基础医学研究所, 2016.
	SHI X H. Expression and clinical significance of soluble Tim-3 in different diseases[D]. Beijing: Institute of Basic Medical Sciences, Academy of Military Medical Sciences, 2016.
[12]	ZHANG J, ZHAN F, LIU H L. Expression level and significance of Tim-3 in CD4+ T lymphocytes in peripheral blood of patients with coronary heart disease[J]. Braz J Cardiovasc Surg, 2022, 37(3):350-355. doi:10.21470/1678-9741-2020-0509.
[13]	HOU N, ZHAO D, LIU Y, et al. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis[J]. Atherosclerosis, 2012, 222(1):67-73. doi:10.1016/j.atherosclerosis.2012.02.009.
[14]	HAO H, HE M, LI J, et al. Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 194:85-91. doi:10.1016/j.ejogrb.2015.08.022.
[15]	HIRASHIMA M, KASHIO Y, NISHI N, et al. Galectin-9 in physiological and pathological conditions[J]. Glycoconj J, 2002, 19(7/8/9):593-600. doi:10.1023/B:GLYC.0000014090.63206.2f.
[16]	SAKAI K, KAWATA E, ASHIHARA E, et al. Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis[J]. Eur J Immunol, 2011, 41(1):67-75. doi:10.1002/eji.200939931.
[17]	MANSOUR A A, RAUCCI F, SAVIANO A, et al. Galectin-9 regulates monosodium urate crystal-induced gouty inflammation through the modulation of Treg/Th17 ratio[J]. Front Immunol, 2021, 12:762016. doi:10.3389/fimmu.2021.762016.
[18]	SUN L, ZOU S, DING S, et al. Circulating T cells exhibit different TIM3/Galectin-9 expression in patients with obesity and obesity-related diabetes[J]. J Diabetes Res, 2020, 2020:2583257. doi:10.1155/2020/2583257.
[19]	KUROSE Y, WADA J, KANZAKI M O, et al. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease[J]. BMC Nephrol, 2013, 14:23. doi:10.1186/1471-2369-14-23.
[20]	SU Z, WANG T, ZHU H, et al. HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion[J]. Immunobiology, 2015, 220(5):539-544. doi:10.1016/j.imbio.2014.12.009.
[21]	BEHL T, SHARMA E, SEHGAL A, et al. Expatiating the molecular approaches of HMGB1 in diabetes mellitus:Highlighting signalling pathways via RAGE and TLRs[J]. Mol Biol Rep, 2021, 48(2):1869-1881. doi:10.1007 /s11033-020-06130-x.
[22]	CHEN Y, QIAO F, ZHAO Y, et al. HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose[J]. Int J Clin Exp Pathol, 2015, 8(6):6683-6691.
[23]	BENLIER N, ERDOĞAN M B, KEÇIOĞLU S, et al. Association of high mobility group box 1 protein with coronary artery disease[J]. Asian Cardiovasc Thorac Ann, 2019, 27(4):251-255. doi:10.1177/0218492319835725.

组别	n	男性	年龄（岁）	BMI（kg/m²）	FBG（mmol/L）	HbA1c（%）
Con组	48	23（47.9）	51.00（47.00，55.00）	22.05±3.37	5.19（4.88，5.57）	4.80（4.43，5.20）
T2DM组	50	26（52.0）	51.50（47.75，58.25）	25.15±3.07^a	9.68（8.15，11.63）^a	8.67（7.88，9.49）^a
T2DM+CHD组	52	25（48.1）	51.00（47.00，58.00）	26.64±3.58^ab	12.25（8.86，15.92）^a	9.00（7.33，11.45）^a
χ²/F		0.214	0.780	24.245^＊＊	102.050^＊＊	97.268^＊＊

组别	n	男性	年龄（岁）	BMI（kg/m²）	FBG（mmol/L）	HbA1c（%）
Con组	48	23（47.9）	51.00（47.00，55.00）	22.05±3.37	5.19（4.88，5.57）	4.80（4.43，5.20）
T2DM组	50	26（52.0）	51.50（47.75，58.25）	25.15±3.07^a	9.68（8.15，11.63）^a	8.67（7.88，9.49）^a
T2DM+CHD组	52	25（48.1）	51.00（47.00，58.00）	26.64±3.58^ab	12.25（8.86，15.92）^a	9.00（7.33，11.45）^a
χ²/F		0.214	0.780	24.245^＊＊	102.050^＊＊	97.268^＊＊

组别	n	sTIM-3（ng/L）	Gal-9（ng/L）	HMGB1（ng/L）
Con组	48	169.31（149.28，187.71）	361.47±76.92	823.73（757.03，901.77）
T2DM组	50	203.95（169.46，240.09）^a	407.37±52.80^a	940.95（857.03，1 019.66）^a
T2DM+CHD组	52	252.81（199.47，330.65）^ab	441.36±76.84^ab	998.39（879.48，1 087.47）^a
F		43.253^＊＊	16.522^＊＊	34.700^＊＊

组别	n	sTIM-3（ng/L）	Gal-9（ng/L）	HMGB1（ng/L）
Con组	48	169.31（149.28，187.71）	361.47±76.92	823.73（757.03，901.77）
T2DM组	50	203.95（169.46，240.09）^a	407.37±52.80^a	940.95（857.03，1 019.66）^a
T2DM+CHD组	52	252.81（199.47，330.65）^ab	441.36±76.84^ab	998.39（879.48，1 087.47）^a
F		43.253^＊＊	16.522^＊＊	34.700^＊＊

变量	AUC（95%CI）	敏感度（%）	特异度（%）	截断值（ng/L）	约登指数
sTIM-3	0.794（0.722~0.867）	62.75	87.50	204.28	0.50
Gal-9	0.735（0.651~0.820）	50.00	85.42	422.41	0.35
联合诊断	0.812（0.743~0.882）	67.65	83.33	—	0.51

sTIM-3及其配体Gal-9、HMGB1与2型糖尿病并发冠心病的相关性研究

Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 5

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

因素	β	SE	Wald χ²	P	OR（95%CI）
BMI	0.213	0.062	11.690	0.001	1.237（1.095，1.833）
年龄	0.022	0.023	0.874	0.350	1.022（0.976，1.070）
sTIM-3	0.013	0.004	8.287	0.004	1.013（1.004，1.021）
Gal-9	0.007	0.004	3.870	0.049	1.007（1.000，1.015）
HMGB1	-0.001	0.002	0.193	0.660	0.999（0.996，1.002）
常数项	-12.300	2.777	19.620	<0.001	<0.001

[1]	林峰, 陈铃雄, 刘羽, 张旭明, 尹志达, 林坛辉, 刘尊荣. 紫杉醇涂层球囊治疗2型糖尿病膝下动脉严重病变患者发生远期再狭窄预测模型的构建[J]. 天津医药, 2024, 52(8): 830-834.
[2]	王娴, 刘霞明, 陈曼玉, 赵君, 王立东. 基于机器学习对2型糖尿病肾病预测模型的构建及验证[J]. 天津医药, 2024, 52(7): 775-780.
[3]	涂静, 夏晨曦, 李婷. 2型糖尿病亚临床周围神经病变与TIR的相关性及危险因素探讨[J]. 天津医药, 2024, 52(11): 1188-1192.
[4]	左宪宏, 张婷婷, 李月琴, 赵佳琪. 沉默Salusin-β对糖尿病大鼠内皮功能障碍的影响及机制研究[J]. 天津医药, 2023, 51(5): 491-497.
[5]	姚坤妹, 夏中华, 黄兴杰, 黄敏, 刘琼, 周汉力. 冠状动脉慢血流患者血清GDF-15和hs-CRP水平变化及临床意义[J]. 天津医药, 2023, 51(4): 418-421.
[6]	钟慕贤, 谢新荣. 糖尿病酮症酸中毒合并新型冠状病毒肺炎的临床特征分析[J]. 天津医药, 2023, 51(12): 1378-1381.
[7]	谭安隽, 杨晶晶, 李天荣. 鸢尾素与新诊断2型糖尿病的相关性研究[J]. 天津医药, 2023, 51(1): 91-94.
[8]	杨超, 张志永. 2型糖尿病患者结直肠腺瘤发病的多因素风险预测模型构建[J]. 天津医药, 2023, 51(1): 95-99.
[9]	王勇, 牛伟华, 卢成志, 许梦萍, 徐建强, 何强, 许学升. 去肾交感神经对2型糖尿病大鼠血管内皮细胞自噬及NLRP3活化的影响[J]. 天津医药, 2022, 50(8): 810-816.
[10]	陈蒙, 张颖, 刘玉洁. NSTE-ACS合并2型糖尿病患者非罪犯病变斑块负荷的研究[J]. 天津医药, 2022, 50(7): 739-743.
[11]	姚明言, 张靖, 王杰, 李志红△, 尹飞. 利拉鲁肽联合德谷胰岛素对2型糖尿病患者血糖波动的影响[J]. 天津医药, 2022, 50(6): 663-667.
[12]	陈灵芝, 钟开义, 陈立国. MTHFR基因启动子甲基化与糖尿病肾病发病的关系研究[J]. 天津医药, 2022, 50(6): 633-638.
[13]	田志霞, 李恒, 韦丽, 于雪芳, 贾俊亚, 闫铁昆, 李栋. 2型糖尿病对原发性膜性肾病临床转归的影响[J]. 天津医药, 2022, 50(12): 1292-1296.
[14]	李英, 张洁, 余红艳, 杨玲, 邸阜生. 2型糖尿病合并脂肪肝患者的心肺耐力情况及其影响因素分析[J]. 天津医药, 2022, 50(12): 1320-1323.
[15]	张树杰, 张瑞清, 郑宪玲, 张凯. 基础胰岛素联合口服药治疗血糖控制不佳的2型糖尿病患者的影响因素研究[J]. 天津医药, 2022, 50(11): 1192-1195.